Welcome to our dedicated page for Fulgent Genetics news (Ticker: $FLGT), a resource for investors and traders seeking the latest updates and insights on Fulgent Genetics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Fulgent Genetics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Fulgent Genetics's position in the market.
Fulgent Pharma, a subsidiary of Fulgent Genetics (NASDAQ: FLGT), presented Phase 1 clinical data on FID-007, its lead therapeutic oncology candidate, at the ASCO Annual Meeting on June 2, 2024. The study involved 11 patients with head and neck squamous cell carcinoma (HNSCC). Results showed a 45% partial response (PR) rate and a 27% stable disease (SD) rate. Three out of five patients with PR had previously been treated with taxane. The follow-up duration ranged from 1 to 15 months, and no high-grade neuropathy was observed. FID-007 demonstrated preliminary antitumor activity and lower toxicity. Fulgent has initiated a Phase 2 study of FID-007 in combination with cetuximab for HNSCC patients.
Fulgent Pharma, a subsidiary of Fulgent Genetics (NASDAQ: FLGT), announced the presentation of Phase 1 clinical data on its lead oncology candidate, FID-007, at the ASCO 2024 Annual Meeting. FID-007, a novel nanoparticle paclitaxel formulation, is being studied for the treatment of head and neck squamous cell carcinoma. The presentation will take place on June 2, 2024, in Chicago, Illinois, in a poster session during the Head and Neck Cancer track. Specific details include the abstract title, session, date, time, and poster board number.
Moffitt Cancer Center and Fulgent Pharma, a subsidiary of Fulgent Genetics (NASDAQ: FLGT), have announced a strategic partnership aimed at advancing cancer treatment. This collaboration combines Moffitt’s clinical capabilities with Fulgent’s nanotherapeutics and genomics platforms to accelerate the development of personalized cancer therapies.
Under the agreement, Moffitt will provide Fulgent with priority access to its clinical resources to expedite the advancement of Fulgent’s clinical pipeline. Fulgent's nanoencapsulation technology has already transformed paclitaxel into the soluble FID-007, showing substantial tumor reduction in Phase 1 studies.
The partnership will also co-develop next-generation personalized treatment options, leveraging Moffitt's scientific expertise and Fulgent's nano-particle-based drug development platform and genetic testing capabilities.
Brixton Biosciences has announced a successful Series B funding round, raising $33M. The funds will be used to advance their Neural Ice™ platform, a drug-free, injectable nerve block designed to provide long-lasting pain relief for 3-6 months. This funding will support pivotal clinical studies targeting knee pain from osteoarthritis and knee replacement surgery. The round was led by Schooner Capital, with participation from several other investors. The company also announced the appointment of Dr. Michael Fishman as Chief Medical Officer and industry veteran Reggie Groves to the Board of Directors. The Neural Ice™ platform has received Breakthrough Device Designation from the FDA, and early clinical results are promising.
Fulgent Genetics, Inc. (NASDAQ: FLGT) announced its first quarter 2024 financial results, reporting a total revenue of $64.5 million with core revenue growing 1% year-over-year to $63.2 million. The company reiterated its full-year 2024 core revenue guidance of $280 million. Despite a GAAP loss of $13.5 million, or $0.45 per share, Fulgent showed a non-GAAP loss of $269,000, or $0.01 per share. The adjusted EBITDA loss was $3.2 million, with cash from operations at $7.3 million. Fulgent's cash, cash equivalents, and investments in marketable securities were $846.2 million as of March 31, 2024. The company highlighted strong momentum in Precision Diagnostics and milestones in its therapeutic development business, including progress in clinical testing for lead oncology drug candidate FID-007. Fulgent maintains a positive outlook for the full year 2024, expecting core revenue of approximately $280 million and a strong financial position with ample cash to execute.
